What is Pramlintide?
Pramlintide — sold under the brand name Symlin — is a synthetic version of a hormone your body makes naturally called amylin. Amylin is a 37-amino-acid peptide released by the pancreas alongside insulin every time you eat.[1] In people with diabetes, amylin production is reduced or absent, which leaves an important piece of the blood-sugar puzzle missing.[6] Pramlintide is produced using recombinant DNA technology — essentially, lab-engineered bacteria build the peptide to exact specifications.[4] It is classed as an amylin analog and sits within the broader GLP-1 / metabolic peptide research category. On this page we treat it strictly as a research compound for educational purposes.
How Pramlintide Works
Think of amylin as insulin's quieter partner. Insulin is the main signal that tells cells to absorb sugar from the blood. Amylin handles three supporting jobs that insulin alone can't do:
- Slows gastric emptying. Food moves from the stomach into the intestine more slowly, so sugar enters the bloodstream in a gentler wave instead of a flood.[1]
- Suppresses glucagon. Glucagon is a hormone that tells the liver to release stored sugar. Amylin keeps glucagon in check after meals, preventing unnecessary sugar spikes.[1]
- Signals the brain to stop eating. Amylin acts on areas of the brain called circumventricular organs — regions that sit outside the blood-brain barrier — to promote satiety, meaning the feeling of fullness.[1]
Pramlintide mimics all three of these actions. Because it is a peptide (a short protein chain), it must be injected rather than swallowed — stomach acid would break it down before it could do anything useful.[4]
What the Research Shows
Decades of research have built a solid picture of how amylin and pramlintide behave in the body.
A landmark 2015 review in Pharmacological Reviews laid out amylin's broad role as a glucoregulatory hormone — meaning it helps keep blood sugar balanced. The review found that amylin interacts with other metabolic hormones including leptin, cholecystokinin, and estradiol, hinting at complex, system-wide effects beyond simple glucose control.[1] The same review noted that amylin agonists (compounds that activate amylin receptors) showed promise for weight loss, particularly when combined with other agents.[1]
A 2024 review in the International Journal of Molecular Sciences described amylin as an anorexigenic hormone — a term meaning it suppresses appetite. The authors highlighted pramlintide's dual role: it addresses both glucose homeostasis and the hedonic (pleasure-driven) aspects of eating, making it relevant to research on obesity as well as diabetes.[6]
A 2025 review in Endocrine Reviews noted that pramlintide is among several agents being studied to address insulin resistance in type 1 diabetes — a condition more common in that population than previously appreciated.[2] The authors acknowledged that while promising, pramlintide's off-label use and short duration of action currently limit its wider adoption.[2]
Pramlintide's short half-life has driven researchers to look for improved versions. Scientists at Novo Nordisk developed cagrilintide, a long-acting amylin analog, partly because pramlintide requires up to three daily injections due to how quickly it clears the body.[3] This next-generation compound is now in clinical trials, including in combination with the GLP-1 analog semaglutide.[3]
What Pramlintide Is Being Studied For
- Post-meal glucose control — reducing blood sugar spikes after eating in both type 1 and type 2 diabetes models.[1]
- Appetite and weight regulation — amylin receptor activation promotes satiety and has shown body-weight-reducing effects in research settings.[6]
- Insulin resistance — early-stage research suggests pramlintide may help address insulin resistance as part of a broader metabolic strategy.[2]
- Combination metabolic therapies — researchers are exploring amylin analogs alongside GLP-1 receptor agonists and other hormones to amplify metabolic benefits.[1][3]
How Pramlintide Is Dosed in Research
Dosing protocols for pramlintide vary depending on the research context and the model being studied. Because no dosing rows have been added yet, please refer to the dosage chart on this page for specific reference ranges as they become available, and use the on-page calculator to work through weight-based dosing calculations. What is consistent across published literature is that pramlintide is administered by subcutaneous injection (under the skin) and has a notably short half-life, which in human clinical use has historically required multiple daily injections.[3] Research protocols should account for this rapid clearance when designing timing and frequency of administration.
Mixing and Storing Pramlintide
Pramlintide is a peptide, so proper handling matters. In research settings it is typically supplied as a lyophilized (freeze-dried) powder or as a pre-made solution. If working with a lyophilized form, reconstitute with the solvent specified by your supplier — commonly bacteriostatic water or sterile saline — using slow, gentle swirling rather than vigorous shaking to avoid denaturing (breaking down) the peptide. Avoid mixing pramlintide with insulin in the same syringe, as the two compounds are physically incompatible when combined.[4] Store unmixed vials in a refrigerator (around 2–8 °C / 36–46 °F) and protect them from light. Once reconstituted, follow your supplier's guidance on shelf life — peptide solutions degrade over time even when refrigerated. Always label vials with the date of reconstitution. This compound is for research use only; these mixing notes are not medical instructions.
Sources
- Amylin: Pharmacology, Physiology, and Clinical Potential. — Pharmacological reviews, 2015. PMID 26071095.
- Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance. — Endocrine reviews, 2025. PMID 39998445.
- Development of Cagrilintide, a Long-Acting Amylin Analogue. — Journal of medicinal chemistry, 2021. PMID 34288673.
- Pramlintide. — , 2012. PMID 31644254.
- Pramlintide. — , 2006. PMID 30000033.
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. — International journal of molecular sciences, 2024. PMID 38338796.
EN
BR
ES
FR
DE
RU